Based on the findings that the glitazone-class antidiabeticagents and fibrate-class antidyslipidemic agents are ligands of PPARγ and PPARα, respectively, much researchinterest has been focused on these two metabolic NR subtypes as therapeutictargets for the treatment of diabetes and dyslipidemia. This evidence concerns the gene PPARA and metabolic syndrome.